Global Generic Oncology Sterile Injectable Market, by Product Type (Chemotherapy (Alkylating Agents, Antimetabolites, Plant Alkaloids, Antitumor Antibiotics, and Others), Monoclonal Antibodies, Cytokines, and Peptide Hormones), by Disease Indication (Ovarian Cancer, Breast Cancer, Lung Cancer, Pancreatic Cancer, and Others), by Distribution Channel (Hospital Pharmacies,  Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), was valued at US$  11,496.7million in 2019 and is expected to exhibit a CAGR of 11.5% over the forecast period (2019-2027).

Manufacturers in the market are focusing on collaboration and expansion of manufacturing facilities to tap into emerging markets. For instance, in July 2017, India-based Alembic Pharmaceuticals established an oncology manufacturing facility for injectables and lyophilized products in Gujarat. The manufacturing site has a capacity for 60 million tablets and capsules and around 20 million vials capacity for liquid injectables and lyophilized product. This new manufacturing facility will develop oncology injectables and lyophilized products for sales in the U.S., Middle East, North Africa, South Africa, and Australia. Furthermore, in December 2016, the global leader, Baxter International acquired India-based Claris Injectables for expanding its generic injectables product portfolio such as in oncology. This acquisition is expected to strengthen Baxter’s sales in hospitals, thereby gaining a leading position in the generic injectables market. Also, in August 2017, Hikma Pharmaceuticals increased its additional manufacturing capacity by 70 million units exclusively for oncology injectables, which brings up its total to 550 million units. Therefore, this expansion will help Hikma to maintain its position in the market.

In October 2014, Sagent Pharmaceuticals, Inc., acquired Omega Laboratories Limited. This acquisition is expected to aid in creating a robust product portfolio of generic injectables and expand Sagent’s global presence. Omega has a strong pipeline consisting of 26 generic injectables, which are planned to be launched between 2014 and 2019.

Furthermore, in October 2017, Eli Lilly & Company received intellectual property rights for the vitamin regimen for Alimta (pemetrexed for injection) from the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office (PTO). These rights are expected to aid Eli Lilly & Company in the development of next generation medicines.

Browse 35 Market Data Tables and 39 Figures spread through 151 Pages and in-depth TOC on "Global Generic Oncology Sterile Injectable Market, by Product Type (Chemotherapy (Alkylating agents, Antimetabolites, Plant Alkaloids, Antitumor Antibiotics, and Others), Monoclonal Antibodies, Cytokines, and Peptide Hormones), by Disease Indication (Ovarian Cancer, Breast Cancer, Lung Cancer, Pancreatic Cancer, and Others), by Distribution Channel (Hospital Pharmacies,  Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)  - Global Forecast to 2027"

To know the latest trends and insights related to global Generic Oncology Sterile Injectable market, click the link below:

https://www.coherentmarketinsights.com/market-insight/generic-oncology-sterile-injectables-market-562

Manufacturers in the market are focusing on collaboration for expanding their product portfolio, which is expected to boost the market growth during the forecast period. For instance, in 2017, Baxter international Inc. entered into an exclusive strategic partnership with ScinoPharm Taiwan, Ltd. to develop, manufacture, and commercialize five injectable drugs used in a range of cancer treatments, including lung cancer, multiple myeloma, and breast cancer.

Key Takeaways of the Global Generic Oncology Sterile Injectable Market:

  • The global generic oncology sterile injectable market is expected to exhibit a CAGR of 11.5% over the forecast period (2019–2027), owing to increasing launches of generic oncology sterile injectables
  • Among disease indication, ovarian cancer segment is expected to account for a major revenue share by 2027, owing to increasing incidence of ovarian cancer. For instance, according to the National Cancer Institute, in 2019, total of 22,530 new cases of ovarian cancer were registered in the U.S.
  • Major players operating in the global generic oncology sterile injectable market include Eli Lilly & Company, Biocon Ltd., Baxter International Inc., Hikma Pharmaceuticals PLC, Mylan N.V., Sandoz International GmbH, Teva Pharmaceutical Industries Ltd., and Pfizer Inc.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner